Abstract
Importance
Fluoroquinolones have been associated with collagen degradation, raising safety concerns related to more serious collagen disorders with use of these antibiotics, including aortic aneurysm and dissection.Objective
To examine the relationship between fluoroquinolone therapy and the risk of developing aortic aneurysm and dissection.Design, setting, and participants
We conducted a nested case-control analysis of 1477 case patients and 147 700 matched control cases from Taiwan's National Health Insurance Research Database (NHIRD) from among 1 million individuals longitudinally observed from January 2000 through December 2011. Cases patients were defined as those hospitalized for aortic aneurysm or dissection. One hundred control patients were matched for each case based on age and sex.Exposures
Current, past, or any prior-year use of fluoroquinolone. Current use was defined as a filled fluoroquinolone prescription within 60 days of the aortic aneurysm or dissection; past use refers to a filled fluoroquinolone prescription between 61 and 365 days prior to the aortic aneurysm; and any prior-year use refers to having a fluoroquinolone prescription filled for 3 or more days any time during the 1-year period before the aortic aneurysm or dissection.Main outcomes and measures
Risk of developing aortic aneurysm or dissection.Results
A total of 1477 individuals who experienced aortic aneurysm or dissection were matched to 147 700 controls. After propensity score adjustment, current use of fluoroquinolones was found to be associated with increased risk for aortic aneurysm or dissection (rate ratio [RR], 2.43; 95% CI, 1.83-3.22), as was past use, although this risk was attenuated (RR, 1.48; 95% CI, 1.18-1.86). Sensitivity analysis focusing on aortic aneurysm and dissection requiring surgery also demonstrated an increased risk associated with current fluoroquinolone use, but the increase was not statistically significant (propensity score-adjusted RR, 2.15; 95% CI, 0.97-4.60).Conclusions and relevance
Use of fluoroquinolones was associated with an increased risk of aortic aneurysm and dissection. While these were rare events, physicians should be aware of this possible drug safety risk associated with fluoroquinolone therapy.Full text links
Read article at publisher's site: https://doi.org/10.1001/jamainternmed.2015.5389
Read article for free, from open access legal sources, via Unpaywall: https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2451282/ioi150086.pdf
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1001/jamainternmed.2015.5389
Article citations
Effect of FluoRoquinolones on Aortic Growth, aortic stIffness and wave refLEctionS (FRAGILES study).
Life (Basel), 14(8):992, 09 Aug 2024
Cited by: 0 articles | PMID: 39202735 | PMCID: PMC11355559
Vascular Endothelial Growth Factor Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection.
JAMA Netw Open, 7(3):e240940, 04 Mar 2024
Cited by: 0 articles | PMID: 38436956 | PMCID: PMC10912963
Safety of fluoroquinolones.
Rev Esp Quimioter, 37(2):127-133, 22 Dec 2023
Cited by: 0 articles | PMID: 38140798 | PMCID: PMC10945095
Review Free full text in Europe PMC
Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing Trends.
Drug Saf, 46(4):405-416, 28 Mar 2023
Cited by: 4 articles | PMID: 36976448 | PMCID: PMC10044099
Investigation of the Pathogenic Mechanism of Ciprofloxacin in Aortic Aneurysm and Dissection by an Integrated Proteomics and Network Pharmacology Strategy.
J Clin Med, 12(4):1270, 06 Feb 2023
Cited by: 3 articles | PMID: 36835806 | PMCID: PMC9967027
Go to all (81) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case-control study.
BMC Cardiovasc Disord, 22(1):44, 13 Feb 2022
Cited by: 4 articles | PMID: 35152888 | PMCID: PMC8842902
Association Between Fluoroquinolone Use and Hospitalization With Aortic Aneurysm or Aortic Dissection.
JAMA Cardiol, 8(9):865-870, 01 Sep 2023
Cited by: 3 articles | PMID: 37585175 | PMCID: PMC10433140
Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis.
Cardiovasc Hematol Agents Med Chem, 17(1):3-10, 01 Jan 2019
Cited by: 14 articles | PMID: 30947680 | PMCID: PMC6865049
Review Free full text in Europe PMC
Fluoroquinolones and the Risk of Aortopathy: A Systematic Review and Meta-Analysis.
WMJ, 119(3):185-189, 01 Sep 2020
Cited by: 4 articles | PMID: 33091293
Review